Introduction: Direct-to-consumer personal genomic testing has the potential to influence health behaviors, including smoking. Critics of this testing highlight limited evidence to support positive behavioral benefits and caution that genomic results may provide false reassurance, leading to unhealthy behaviors. This study investigates interest in genetic risks of smoking-related diseases and changes in smoking behaviors among genomic testing consumers. Methods: From 2012 to 2013, a longitudinal series of web surveys was conducted. A total of 1464 customers of 23andMe and Pathway Genomics completed a survey prior to viewing genomic test results, of which 1002 participants provided data on smoking behaviors 6 months after receiving results. Results: At baseline, 64% of participants were never smokers, 29% were former smokers, and 7% were current smokers. Most baseline current smokers were very interested in genetic risk results for lung cancer (65%) and heart disease (72%). For lung cancer, this interest was significantly greater than former (50% very interested) and never smokers (37% very interested) (p < .0001). Even though participants were interested in smoking-related disease genetic risks, 96% reported the same smoking status at baseline and 6-month follow-up. Importantly, only 1% (n = 13/916) of former and never smokers became current smokers at 6 months and 22% (n = 14/64) of current smokers reported quitting. Conclusions: Overall, smokers show a high level of interest in genetic risks of smoking-related illnesses. The experience of receiving direct-to-consumer genomic health risks does not appear to have obvious harms related to smoking behaviors, with some potential benefits. Implications: In the setting of ongoing controversy surrounding direct-to-consumer genomic testing, this study provides evidence that consumers are interested in genetic risk results of smokingrelated diseases. Receiving genomic testing results does not lead to smoking initiation among never smokers or reinitiation among former smokers and may be associated with a higher quit rate among current smokers at 6-month follow-up than the general population. These findings ease concerns that direct-to-consumer genomic testing could lead to false reassurance and unhealthy behaviors related to smoking.
Introduction
Over the last decade, we have witnessed an explosion in the popularity and availability of personal genomic risk information, especially in the context of direct-to-consumer testing. This rapid growth has sparked controversy regarding the regulation of direct-to-consumer testing companies, [1] [2] [3] leading the Food and Drug Administration to order 23andMe to remove health-related interpretations from its services in 2013 4 before 23andMe adopted offerings to meet regulations in 2015. 5 Studies on the behavioral implications of direct-toconsumer genomic testing are warranted to inform current policies.
The question of whether personal genomic risk information can be harnessed to positively influence health behaviors has received considerable attention. [6] [7] [8] [9] Early empirical studies on the effect of returning genomic information to motivate health behaviors, including healthy dietary intake, physical activity, alcohol consumption reduction, and smoking cessation, have overall been underwhelming, [10] [11] [12] with only a few studies showing a positive behavioral impact of genetic risk information. 13, 14 Limited studies have examined potential negative consequences of returning personal genomic risks, and critics question whether results may lead to false reassurance and unhealthy behaviors. 9, 15, 16 As a leading cause of preventable death in the United States and worldwide, 17, 18 smoking is an ideal health behavior for studying the influence of personal genomic information. This study investigates: (1) interest in genetic risk for smoking-related disease among current, former, and never smokers and (2) changes in smoking behaviors among customers of two genomic testing companies. By examining the important behavior of cigarette smoking, this analysis seeks to elucidate the potential benefits and harms of direct-to-consumer genomic testing.
Methods

Participants and Procedures
From March to July 2012, the Impact of Personal Genomics (PGen) Study recruited new customers of two personal genomic testing companies (23andMe and Pathway Genomics), which provided health results directly to consumers during the study period. Details of the PGen Study are published elsewhere. 19, 20 A total of 1464 participants completed a baseline survey prior to viewing health-related genomic testing results and were eligible for follow-up. Smoking variables were available on all but one participant at baseline, who was dropped in analyses. Six months following receipt of genomic results, participants received a follow-up survey. A total of 1042 participants responded to this survey (71% of baseline participants), of which 1002 provided smoking measures.
Survey Instruments
Baseline measures included demographics and interest in genetic risk information. Participants were asked "How interested are you in learning about your genetic risk" for lung cancer and heart disease (coronary artery disease), with response choices of not at all, somewhat, and very interested. We focused on these two complex diseases because smoking status is highly related to risk, smoking cessation is critical for prevention, and both companies returned genetic risk information about these diseases.
At both baseline and 6-month follow-up, smoking status was evaluated. Never smokers were individuals who had not smoked 100 cigarettes in their lifetime. Former smokers had smoked 100 cigarettes, but did not smoke anymore. Current smokers had smoked 100 cigarettes and reported smoking some days or every day. Among current smokers, smoking quantity was assessed with the question "How many cigarettes per day do you smoke?" with the responses 10 or fewer, 11-20, 21-30, or 31 or more.
Genetic Risk Estimates
Participants received their personal genomic results online directly from the companies along with information on the average population risk and environmental risk factors. Lung cancer genetic risk was based on one variant in 23andMe (rs8034191) and three variants in Pathway Genomics (rs3117582, rs1051730, and rs2736100). Heart disease genetic risk was based on multiple variants in 23andMe (rs10757278, rs12526453, rs1746048, rs1122608, rs9982601, rs17465637, rs6725887, rs2306374, rs3798220, rs11556924, rs579459, rs12413409, rs964184, rs4773144, and rs2895811) and Pathway Genomics (rs8055236, rs2259816, rs501120, rs3008621, rs2943634, rs383830, rs17411031, rs1333049, rs9818870, rs6922269, rs688034, and rs17228212).
Participants' genetic risk results from 23andMe and Pathway Genomics were linked with PGen survey responses. We evaluated a previously described dichotomous outcome according to whether individuals received an elevated versus average or reduced genetic risk estimate for lung cancer or heart disease. 20 These dichotomous genetic risk outcomes were developed after consultation with both testing companies and used a relative risk threshold, where individuals with a risk of 1.2 or more for each respective disease were considered elevated.
Statistical Analysis
Statistical analyses were performed using Statistical Analysis System (SAS v. 9.3, Cary, NC). Across the smoking status categories (never, former, current), differences in dichotomous demographic variables were evaluated using chi-square goodness of fit. For continuous demographic variables, differences were evaluated using analysis of variance. Logistic regression was used to model the effect of smoking status on interest level of lung cancer and heart disease genetic risk. These models were adjusted for significant differences in demographic factors between groups, and the proportional odds assumption was satisfied. Power calculations indicated more than 90% power with an alpha of 0.05 to detect an effect of smoking status on interest level in lung cancer or heart disease risk with an odds ratio of 1.5. Changes in smoking status occurred when participants switched categories (never, former, current) between baseline and follow-up interviews. In secondary analyses, we examined associations between dichotomous genetic risk scores and changes in smoking behaviors using Fisher's exact test with two-sided p values. Power calculations indicated 54%-98% power to detect a threefold increase (reference proportion of participants with elevated risk ranged from 0.17 to 0.30).
Results
Participant Characteristics
The majority of PGen Study participants were female (61%), selfreported White race (90%), US residents (98%), health insured (95%), and college graduates (78%) (n = 1463, Table 1 ). At baseline, 64% were never smokers, 29% were former smokers, and 7% were current smokers. These smoking status groups differed by age (p < at Harvard Library on October 7, 2016 http://ntr.oxfordjournals.org/ Downloaded from .0001), self-identified White race (p < .05) and Asian race (p < .05), college education (p < .0001), and household income (p < .005).
Comparing participants with 6-month follow-up information on smoking variables (n = 1042) to those without (n = 421), there were no differences in smoking status or genetic risk for lung cancer or heart disease (chi-square p > . 3 ). An additional 22 participants (2%) were excluded because of inconsistent responses (reported smoking 100 cigarettes at baseline but never smoking at follow-up).
Interest in Genetic Risk for Lung Cancer and Heart Disease
Current smokers expressed the most interest in their lung cancer genetic risk (65% very, 28% somewhat, and 6% not at all), compared to former smokers (50% very, 35% somewhat, and 15% not at all), and never smokers (37% very, 42% somewhat, and 21% not at all) ( Table 1 ). This ordered effect was significant (odds ratio = 1.8, 95% CI = 1.5-2.1, p < .0001) after controlling for differences in demographic variables.
Overall, participants were more interested in their heart disease genetic risk (68% very, 26% somewhat, and 5% not at all) compared to lung cancer (42% very, 39% somewhat, 19% not at all) ( Table 1) . Across smoking status groups, there was no significant difference in interest for heart disease genetic risk (p = .8).
Changes in Smoking Behavior
The majority of participants examined at 6-month follow-up (96%, n = 941/980) had the same smoking status as at baseline (Figure 1 ). Only 13 of the 916 baseline never and former smokers (1%) were current smokers at follow-up. Among the 64 baseline current smokers, 14 (22%) reported that they had quit at 6 months after receiving genetic results. An additional six baseline current smokers reduced their smoking quantity, and only two baseline current smokers increased their smoking quantity.
Secondary analyses revealed that neither lung cancer nor heart disease genetic risk results were significantly different (p > .05) among those who initiated (or reinitiated) smoking compared to 
Discussion
This study examined interest in genetic risk information for lung cancer and heart disease, as well as the impact of personal testing on smoking behaviors in more than 1000 23andMe and Pathway Genomics customers. The majority of baseline current smokers were very interested in receiving lung cancer (65%) and heart disease (72%) genetic risk results. This interest in lung cancer risk was significantly greater in current smokers than former and never smokers, possibly reflecting an understanding of the connection between cigarette consumption and lung cancer. For heart disease risk, all groups were very interested in receiving genetic results for this common disease. Our observation that smokers were interested in genetic results for smoking-related illnesses complements recent findings from a high-risk population of smokers. Hartz et al. 14 found that 61% of participants were interested in genetic results of smoking-related diseases from Pathway Genomics. Given this interest among smokers, receiving direct-to-consumer genomic results may present an opportunity for multicomponent smoking cessation interventions. One of the few trials showing positive behavioral change with return of genetic results also provided nicotine patches and counseling, 13 highlighting that genomic information may be more likely to motivate cessation when combined with other interventions. 6 Even though PGen Study participants were interested in smoking-related disease risks, the majority (96%) had the same smoking status 6 months after receiving results as at baseline. Importantly, among baseline never and former smokers, only 1% (n = 13/916) reported being a current smoker at follow-up, suggesting that false reassurance from genomic findings did not lead consumers to initiate (or reinitiate) smoking. Furthermore, secondary analyses found that rates of elevated lung cancer and heart disease genetic risk were similar between those who started smoking and those who did not. If false reassurance led to smoking initiation, we would expect initiators and reinitiators to more frequently have received an average (vs. elevated) risk of smoking-related diseases. To our knowledge, no previous study has provided evidence that personal genomic testing does not lead to smoking initiation among never smokers or reinitiation among former smokers. These findings may help ease concerns that genomic testing contributes to false reassurance of health risks, which in turn, may lead to an uptake of smoking behaviors.
Among baseline current smokers, 22% (n = 14/64) reported quitting at 6-month follow-up, a higher rate than observed in the general US population. For example, the National Health Interview Survey examined more than 25 000 US adults and found that although 52% of smokers made a quit attempt in the last year, only 6% successfully quit. 21 Though the baseline sample of current smokers in this study was small, these promising results suggest that genomic health information can motivate quitting. However, meta-analyses have shown that although genetic results may increase cessation motivation 11 and behaviors within 6 months, 22, 23 these results are not associated with abstinence at longer follow-ups. A next step is to examine how to propagate these positive behavioral changes over the long term. Importantly, future studies should assess whether genomic risk information in conjunction with psychosocial and pharmacological treatments can support long-term quitting.
This study has limitations. First, we used an available sample recruited through consumers of two genomic testing companies. These early adopters of genomic testing are predominantly White, college-educated individuals with health insurance, and are not representative of the general population. Their interest in testing may bias the results toward more favorable outcomes and limit generalizability. Future research should focus on engaging diverse populations, and previous work highlights that personal contact, incentives, and community engagement are effective strategies for recruitment of minority populations. 24 Second, this longitudinal observational study did not have a control group who did not receive direct-toconsumer testing, limiting conclusions regarding the causality of genomic information on smoking behaviors. Third, a personal or family history of heart disease or lung cancer may influence interest in these conditions. Future research may take advantage of these powerful risk factors for health behaviors that incorporate genetic and environmental influences. Fourth, these analyses are based on one 6-month follow-up and do not provide information on longterm smoking behaviors. Fifth, outcome measures are subject to the limitations of self-reported health behaviors. It is possible that our This study is a first step toward understanding the impact of directto-consumer genomic health testing on cigarette smoking. In the midst of ongoing controversy surrounding direct-to-consumer testing, these results suggest that for the behavior of smoking, genomic results are of interest and have no clear harms with some possible benefits.
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